Enfcate en lo que realmente importa: vender el producto
10 In the DAPA-HF trial, among 4,700 patients with a significantly reduced mean LVEF (31% 6.7), most classified as New York Heart Association (NYHA) class II, dapagliflozin provided a 26% RR reduction in the primary composite outcome (CV death, HF hospitalisation and urgent visits for worsening HF), regardless of the presence or absence of type 2 diabetes (T2D), with a NNT of 21
And thats great, because it means that you get the results that you need for your health
For eligible adults, medicines like the Tirzepatide pen offer something that older treatment approaches often struggled to provide: clinically meaningful weight reduction with strong evidence from large trials and the potential for broader metabolic benefit
When combined with a balanced and varied diet, it can be a great addition to your overall health
, Yu, R